CLINICAL TRIALS PROFILE FOR ONGLYZA
✉ Email this page to a colleague
All Clinical Trials for Onglyza
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00575588 ↗ | 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period | Completed | Bristol-Myers Squibb | Phase 3 | 2007-12-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin. |
| NCT00575588 ↗ | 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period | Completed | AstraZeneca | Phase 3 | 2007-12-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sulphonylurea in addition with metformin. |
| NCT00614939 ↗ | Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment | Completed | Bristol-Myers Squibb | Phase 3 | 2008-01-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients. |
| NCT00614939 ↗ | Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment | Completed | AstraZeneca | Phase 3 | 2008-01-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to test the efficacy of once daily saxagliptin in renally impaired patients. |
| NCT00661362 ↗ | Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes | Completed | Bristol-Myers Squibb | Phase 3 | 2008-06-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise. |
| NCT00661362 ↗ | Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes | Completed | AstraZeneca | Phase 3 | 2008-06-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients who have inadequate glycaemic control when treated with metformin in addition to diet and exercise. |
| NCT00666458 ↗ | 18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D) | Completed | Bristol-Myers Squibb | Phase 3 | 2008-04-01 | Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin in addition with metformin. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Onglyza
Condition Name
Clinical Trial Locations for Onglyza
Trials by Country
Clinical Trial Progress for Onglyza
Clinical Trial Phase
Clinical Trial Sponsors for Onglyza
Sponsor Name
